-
Annexin V-APC/7-AAD Apoptosis Kit Workflow
2026-09-05
Build a rapid, two-parameter workflow that separates viable, apoptotic, late apoptotic, and necrotic cells in cancer and immunology experiments. This guide translates findings from MLL-rearranged leukemia research into practical assay design, flow cytometry gating, microscopy choices, and troubleshooting strategies.
-
Isorhamnetin: Designing Better Oocyte Assays
2026-09-04
Isorhamnetin is a flavonoid research compound linked to PI3K/Akt activation, oxidative-stress control, and improved porcine oocyte maturation. This article presents a decision-centered assay framework for separating phenotype, mechanism, and practical handling variables.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-09-04
The reference study identifies human Nav1.8, TRPV1, and TRPA1 as potential molecular targets of topically applied ambroxol, while revealing marked species differences in Nav1.8 inhibition. Whole-cell patch-clamp experiments show that ambroxol combines sodium-channel inhibition with weaker, concentration-dependent modulation of sensory TRP channels, providing a mechanistic framework for topical neuropathic pain research.
-
Alpha-Ketoglutarate: From TCA Flux to Tumor Immunity
2026-09-03
Alpha-ketoglutarate is more than a tricarboxylic acid cycle intermediate: it can connect mitochondrial metabolism, nitrogen handling, post-translational modification, and immune escape. This translational perspective examines how PDHA1 succinylation-driven α-KGA accumulation may shape cholangiocarcinoma biology and how researchers can use alpha-ketoglutarate as a controlled perturbation in metabolic reprogramming research.
-
Trichostatin A (TSA): From HDAC Biology to Organoids
2026-09-03
Trichostatin A (TSA) is more than a conventional HDAC inhibitor: it is a mechanistic probe for connecting chromatin acetylation with proliferation, differentiation, and phenotypic plasticity. This translational perspective links TSA-driven epigenetic perturbation with recent human intestinal organoid research while clearly separating established evidence from testable hypotheses.
-
Imipenem: Mechanism, Evidence, and Research Use
2026-09-02
Imipenem is a semisynthetic thienamycin antibiotic used as a broad-spectrum antibacterial research tool. Its PBP-directed cell-wall mechanism, immune assay observations, and resistance-modeling relevance are distinct evidence domains that require separate interpretation.
-
Thrombus-Targeting Nanosystems in Arterial and Venous Flow
2026-09-02
The reference study systematically compares molecular recognition, enzyme-driven chemotaxis, and combined targeting in arterial and venous thrombus models. Its central finding is that low-flow venous thrombi can be effectively addressed by chemotactic motion, whereas high-flow arterial thrombi require combined targeting to improve nanosystem retention and thrombolytic efficacy.
-
Hexetidine (NSC-17764) Assay Workflows
2026-09-01
Build more reliable planktonic, biofilm, and combination screens with Hexetidine (NSC-17764), a strain-dependent broad-spectrum antimicrobial for oral infection research. The workflow separates solvent, endpoint, and matrix effects so results can inform dental plaque reduction and gingivitis treatment models without overstating clinical translation.
-
EPO mRNA and the Next Wave of Neurorepair
2026-09-01
Targeted EPO mRNA delivery is reframing erythropoietin from a systemic protein therapy into a locally translated, mechanistically addressable intervention. This article connects Cap 1 and pseudouridine design with emerging evidence on inflammation, ferroptosis, and spinal cord injury repair while outlining a rigorous translational workflow.
-
Measuring Cancer Drug Responses In Vitro
2026-08-31
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a paired, time-aware framework that separates growth inhibition from cell killing, improving interpretation of in vitro pharmacology and experimental design.
-
FITC Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-08-30
Translate O-GlcNAc biology into sharper oocyte imaging and cytometric readouts with a fluorescein-conjugated secondary antibody built for mouse primary antibodies. This practical workflow covers assay design, signal amplification, controls, storage, and troubleshooting for porcine oocyte studies.
-
Fenipentol: Practical Secretion Research Workflows
2026-08-29
Fenipentol, also called 1-Phenyl-1-pentanol, gives researchers a defined small-molecule starting point for secretion physiology, receptor-informed assays, and translational screening. This guide separates direct product evidence from findings on a positional isomer, then converts that distinction into reproducible workflows and troubleshooting decisions.
-
PPM-18: Translating NF-κB–iNOS Insight Into Action
2026-08-29
PPM-18 offers a mechanistically defined way to interrogate the NF-κB–iNOS axis in inflammation and sepsis research. This thought-leadership guide connects transcriptional control of nitric oxide production with translational study design, using osteoimmune evidence to clarify both the opportunity and the limits of cross-domain inference.
-
DiscoveryProbe Bioactive Compound Library Plus Guide
2026-08-28
Build a practical ligand-to-phenotype workflow with 5,072 bioactive compounds, beginning with thermal-shift triage and progressing to orthogonal binding and cell-based validation. The approach helps researchers connect bacterial sensor biology with apoptosis, cancer research, and pathway-focused screening while controlling DMSO, aggregation, and assay artifacts.
-
EZ Cap™ Cas9 mRNA for Gene Editing
2026-08-28
EZ Cap™ Cas9 mRNA (5-moUTP) is capped, polyadenylated, in vitro transcribed Cas9 mRNA for guide-directed genome editing. Its defined RNA format supports transient experimental perturbation, while the cited Fyn–Stat3 zebrafish study provides a mechanistic framework for functional gene studies rather than a direct product-performance benchmark.